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Background: The effect of smoking on blood viscosity is widely known. There are, however, few studies on the
effect of blood viscosity on pulmonary circulation.
Methods: We aimed to observe the relationship between blood viscosity and pulmonary circulation among
smokers and non-smokers. The study comprised 114 subjects in three groups: group 1, ex-smokers; group 2,
smoked at least 10 packs/year and still smoking; group 3, never smoked. Blood viscosity (BV), pulmonary blood flow
(PBF), and right ventricular systolic pressure (RVSP) were measured in all subjects.
Results: PBF was significantly lower in group 1 compared with group 3 (p < 0.05). BV in group 1 was significantly
higher than group 3 (p < 0.05) while BV in group 2 was significantly higher than group 3 (p < 0.05). PBF in group 2
was significantly lower than group 3 (p = 0.01).
Conclusions: We believe that BV is a significant and forgotten factor that plays an important role in pulmonary and
cardiovascular diseases. BV may affect PF even during the course of smoking, and before the clinical onset of
chronic obstructive pulmonary disease (COPD). Therefore, individuals at risk of pulmonary hypertension could be
detected earlier with a simple blood test.Background
Cardiovascular and pulmonary diseases are a significant
cause of mortality worldwide [1-4]. Despite efforts to con-
trol their causes, these diseases are still common and often
fatal. These data suggest that forgotten or neglected etio-
logical factors may be responsible. We believe that blood
viscosity (BV) may be an important factor. To supply ad-
equate oxygen and nutrients to the tissue and organs, the
blood flow rate needs to be of a normal pattern and quan-
tity within the vessels [5-9]. BV is an important factor con-
tributing to normal vessel flow and can be affected by
multiple factors, including hematocrit and smoking. BV
has been studied in COPD, pulmonary hypertension,
anemia, and other blood diseases [10-13]. We aimed to
evaluate the relationship between BV, pulmonary flow rate
(PFR), pulmonary artery pressure (PAP) and right ventricu-
lar systolic pressure (RVSP) in subjects with normal spiro-
metric values, no hypoxemia or COPD, and no disease or* Correspondence: gulfidan70@gmail.com
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in any medium, provided the original work is pdrug usage affecting BV. Thus, we aimed to determine
whether BV could be used to screen healthy individuals,
and to follow-up those individuals with a risk of pulmonary
hypertension before disease onset.
Methods
Study design
The study was initiated following ethics committee ap-
proval from the Istanbul University Cerrahpasa Medical
Faculty. One hundred and fourteen subjects between
35–65 years attending the Clinic of Chest Diseseas as
outpatients with any reason and their healthy volunteer-
ing relatives or friends between January and June 2011
were enrolled in the study. Written consent was
obtained from every individual. Attendants who had any
systemic disorder and/or who had body-mass index
(BMI) greater than 25kg/m2 and/or who were consum-
ing any drugs which might be effecting blood viscosity
were excluded. People who had abnormal biochemical
values of fibrinogen, cholesterol, creatinine, thyroid hor-
mones, and whole blood count were excluded as well.
Blood samples were taken for biochemical parameters,an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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measured, and PFR, PAP and RVSP were determined by
means of echocardiography. Although catheterization is
the best technique for measuring PAP, we preferred
echocardiography as a non-invasive method in healthy
individuals. One hundred and fourteen subjects with no
history of any disease and/or any medications that would
affect BV, and with normal biochemical parameters,
whole blood count, and spirometry (without COPD),
were enrolled in the study.
We divided the subjects into three groups: group1, ex-
smokers (n = 40); group 2, current smokers with at least
10 pack years exposure (n = 34); group 3: never-smokers








Age(year) 51±8 44±7 47±7
Sex(F/M0 20/20 15/19 23/17
BMI(kg/m2) 27.±4.3 27.9±5.4 58.2±4.8
SBP(mmHg) 96±16 95±15 92±16
DBP(mmHg) 70±5 75±7 73±6
Hemoglobin(g/dl) 14.20±1.40 14.80±1.52 12.94±1.48
Hemotocrit(%) 42.58±3.99 43.58±9.47 39.07±5.98a*,b**
FT3(ng/dl) 3.02±0.50 3.21±0.47 3.03±0.45
FT4(ng/dl) 1,18±0.21 1.17±0.15 1.14±0.13
TSH(mIU/L) 24.23±7.40 1.77±0.94a** 1.75±0.83a**
ALT(U/L) 24.23±7.40 23.00±6.68 17.90±5.58a**,b***
AST(U/L) 26.80±7.91 21.91±7.63a* 19.39±6.53a***
Creatinin(mg/dl) 0.90±1.14 4.64±1.06 4.33±1.40
Uric acid(mg/dl) 4.90±1.14 4.64±1.06 4.33±1.40
Cholesterol(mg/dl) 178.71±41.05 179.55±32.38 189.90±30.86
Triglyceride(mg/dl) 105.85±40.64 122.55±59.31 114.74±64.54
LDL(mg/dl) 112.35±36.51 111.93±29±86 119.11±26.21
HDL(mg/dl) 44.19±9.15 43.11±15.14 47.76±10.10b*
Glucose(mg/dl) 94.06±9.55 91.87±7.70 95.78±8.13
Fibrinogen(mg/dl) 405.90±111.60 344.55±78.29 380.86±81.84b*
Leukocyte(103/ml) 7.39±1.92 7.50±1.60 6.80±1.42




SBP; Systolic bloodpressure, DBP; Diastolic blood pressure, Data are mean±SD,
a Statistical comparison with Group 1, b Statistical comparison Group 2 with
Group 3, * p<0,05, **p<0,01, ***p< 0,001.Methods
Tri-iodotyronine (fT3), thyroxine (fT4) and thyroid
stimulating hormone (TSH) were assessed with the
Advia Centaur XP immunoassay device from Siemens
using chemiluminescence, as per the manufacturer’s
instructions. fT3 and fT4 were expressed as ng/dL, and
TSH was expressed as mIU/L. Other biochemical para-
meters were studied using spectrophotometry with the
Advia 2400 device from Siemens Company. Fibrinogen was
assessed using the Claus method with the MDA 180 device
(Trinity Biotech Company) and expressed as mg/dL. The
hemogram was studied using electro-impedance with a
Coulter LH 780 device (Beckman Coulter Company).
Hemoglobin was expressed as g/dL, hematocrit as %, and
leucocyte count was expressed as 103/mL.
BV was measured with Brookfield LVDVIII rotational
viscosimetry at a constant 37°C and at three different
shear rates (23, 115.2, 230 sn-1). Results were expressed
as mPas. To eliminate the effect of hematocrit, which is
accepted as one of the most important factors affecting
BV, it was adjusted to a hematocrit of 45% using the
Quemada equation [10]. These adjusted BV values were
termed ‘corrected BV’, and were reported at shear rates
of 23, 115.2 and 230 l/sec. Spirometric measurements
were performed using the ZAN 100 USB flow handy
device. Vital capacity (VC), forced vital capacity (FVC),
maximum forced expiratory volume in one second
(FEV1), mean forced expiratory flow during mid-half of
the FVC (FEF25-75), and FEV1/FVC were measured. PBF
and RVSP were measured by means of the E Sante My
Lab 60 device using a 2.5 MHz frequency transducer.
Systolic mean blood flow velocity at the pulmonary valve
was measured as m/s with pulse wave Doppler from the
parasternal short axis. RVSP was measured with
continuous wave (cv) Doppler from the apical four
chambers, and tricuspid insufficiency was demonstrated
by detecting jet-stream. RVSP was calculated by adding
right atrium pressure to the right ventricle (RV)-rightatrium (RA) gradient by means of the Bernoulli
principle, and expressed in mmHg.
Analysis
For statistical analysis, NCSS (Number Cruncher Statistical
System) 2007&PASS 2008 Statistical Software (Utah, USA)
was used. Besides descriptive statistical methods (mean,
standard deviation = SD), one-way Anova was used for
intergroup comparisons of quantitative data with normal
distribution. For analysis of variance Tukey HSD was used,
and for relationships between parameters the Pearson’s
correlation coefficient was used. Data were presented as
mean±SD. Results were noted as significant if p < 0.05.
Results
Demographic details and basic biochemical characteris-
tics of the different groups are shown in Table 1. There
were no significant differences between the groups in
terms of gender, age, body mass index (BMI), and PAP
Table 3 Spirometric values of groups
Group 1(n=40) Group 2(n=34) Group 3(n=40)
FVC 3171.6±963.12 2963.25±1031.17 3248.33±662.30
FVC(%) 83.83±13.55 81.23±20.35 94.42±23.43a*,b**
FEV1 2430.00±708.57 2166.75±818.10 2509.41±796.63
FEV1 (%) 76.76±19.60 71.70±20.92 89.50±24.71b*
FEV1/FVC 76.41±8.53 73.05±13.95 79.55±7.54
Data are mean±SD, FVC; Forced Vital Capacity, FEV1; Forced Expiratory Vital
Capacity, FVC; Forced Percentual Vital Capacity, FEV1, Forced Percentual
Expiratory Volume, FEV1/FVC; Tiffeneau Index,
a Statistical comparison with
Group 1, b Statistical comparison Group 2 with Group 3, * p<0,05, **p<0,01.
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19 M, age was 44±7 yrs; and group 3, 23F/17 M, age was
47±7 yrs). There were also no differences in the RVSP
between the groups.
Pulmonary blood flow was 1.05±0.25, 1.00±0.16, and
1.21±0.34 in the three groups respectively. There was no
statistically significant difference in PFR between groups
1 and 2, but PFR in group 3 was significantly higher than
groups 1 and 2 (p < 0.01 and p<0.001, respectively)
(Table 1).
When the hematocrit values were examined, no statis-
tically significant difference was found between group 1
(42.58±3.99%) and group 2 (43.58±9.47%). However, the
hematocrit in group 3 (3.07±5.98%) was significantly
lower than the other two groups (Table 2).
When BV was measured after the hematocrit was stan-
dardized at 45%, the viscosities of group 2 (6.18±1.12
mPas) and group 3 (6.99±0.97 mPas), which repre-
sented middle vessels, were significantly different
from that when the hematocrit was not standardized
(p < 0.001). There was no statistical significant difference
observed in terms of BV between the groups (p > 0.05)
(Table 2).
When the spirometric values of all the groups were
examined, FVC (%) of group 1 versus 3, and group 2 versus
3 showed a statistically significantly higher (p < 0.05 and
p < 0.001, respectively). FEV1 (%) was only significantly
different when group 2 and 3 were compared (61.76±20.92
vs 89.5±24.71, p < 0.05) (Table 3).
When the hematocrit was standardized to 45% the BV
was found to correlate with age, smoking, urea, choles-
terol, and white blood cell count in group 1, and with
age, smoking, and urea in group 2. BV only correlated
with urea in group 3.
Discussion
Blood can carry the necessary nutrients to tissues and
organs as long as it continues its normal flow pattern in
the circulatory system. This normal flow is particularly
important in the pulmonary vascular bed in order that
gas exchange can be performed optimally [14-17]. Vessel
constitution and the fluidity of blood need to be normalTable 2 The values of blood viscosity and blood viscosity
standardized hct at three different shear rate of groups
Group 1(n=40) Group 2(n=34) Group 3(n=40)
Standardized
Hematocrit(%45) 9.28±1.95 9.49±1.69 8.85±1.35 a*,b**
BV (m Pas) 6.26±1.04 6.33±0.91 5.87±1.27
BV (mPas) 4.30±0.51 4.41±0.47 4.04±0.31 b**,a***
Data are mean±SD, BV ; Blood viscosity at shear rate 23 1/sec, BV; ; Blood
viscosity at shear rate 115,2 1/sec, BV; Blood viscosity at shear rate 230 1/sec,
a Statistical comparison with Group 1, b Statistical comparison Group 2 with
Group 3, * p<0,05, **p<0,01, ***p< 0,001.for normal blood flow [18,19]. BV is one of the major
determinants of blood flow and can behave differently in
vessels with different diameters. BV is primarily affected
by hematocrit in medium and large sized vessels, while
it is affected by red blood cell deformability in the capil-
laries [1-9].
High BV causes slowing of blood flow [9,10,12,18]. In
addition to its hematological implications, hematocrit is
functionally important since it is the major determinant of
BV [9,11,20-29]. Our results suggest a significant relation-
ship between blood viscosity, hematocrit, smoking, age,
urea, and spirometric parameters. The effect of smoking on
BV has been reviewed in many studies [1,7,8,13-16]. The
mechanism of action of smoking involves airway obstruc-
tion, vascular endothelial dysfunction, an increase in BV
and a subsequent decrease in pulmonary blood flow
[1,14,15,18-24]. A study by Wannamethee et al. demon-
strated that BV is increased in cigarette smokers. Thus,
smoking is suggested to be an important factor in BV,
which is one of the leading hemostatic factors [25].
Consistent with other studies, hematocrit levels were
found to affect BV, so to exclude this affect, hematocrit
values were fixed to 45% using a standard formula, and an
adjusted BV was calculated. Although the hematocrit
effect was ruled out, the blood viscosities of both current
and former smokers were still higher than the non-
smoking group [8]. This finding suggests that BV may be
emphasized as a risk factor [1,16,26,27,30-32]. Our results
are consistent with previous relevant studies. Increased BV
and decreased pulmonary blood flow play an important
role in the progression of pulmonary hypertension (PH).
PH causes cor pulmonale in chronic obstructive pulmon-
ary disease (COPD) patients and has prognostic relevance
[13,16,20]. Fedde et al. [31] demonstrated the relationship
between BV, pulmonary blood flow, and pulmonary hyper-
tension. Furthermore, Lenz et al. showed the association
between hematocrit and pulmonary blood flow. Following
hemodilution, pulmonary blood flow and exercise capacity
improve [33]. Although there was no significant difference
in RVSP between groups, we found blood flow decreased
in smokers compared with non-smokers. According to the
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sure gradient and vessel diameter, and an inverse relation-
ship with blood flow and vessel length. Thus, pressure
gradient and blood flow are directly proportional. Blood
flow is linearly proportional with pressure gradient and in-
versely proportional with the vessel resistance. Blood flow
is determined by the decrease of pressure from the arteries
to the veins. The resistance is determined by vascular
barrier and BV. An increase in BV causes an increase in
vascular resistance, thus causing a decrease in blood flow.
In light of the foregoing biophysical equations, we suggest
that an increase in BV may cause a decrease in pulmonary
blood flow, and as a result, an increase in pulmonary
artery pressure. This finding may be relevant to the stage
prior to the development of PH.Conclusion
In summary, smoking causes an increase in BV, which
slows PBF. A decrease in PBF without an increase in
RVSP may be an indicator of an early onset of PH. The
results of our study in relation to individuals developing
PH provide valuable data.
Previous studies have shown that BV is increased in
COPD and hypoxemic patients but our study is unique
and important, as the increase in BV could be detected
in smokers before the onset of clinical disease. Thus, we
believe that assessing the risk of PH in its very early
stages may be possible. We wish to emphasize the
importance of BV as a simple parameter for risk assess-
ment in the early stages of PH, and cor pulmonale with
respect to COPD associated mortality [35,36].
This study is limited by its small patient number.
Other parameters that could affect blood viscosity and
hemodynamics are being studied with an increased
number of patients.
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